Internal Medicine, Hematology & Oncology · Knoxville, TN
NPI
1619947876
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
9957 Sherrill Blvd
Knoxville, TN, 37932
Phone (865) 693-2255
Groups this clinician bills Medicare through
Medicare paid, 2024
$8.5M
398,990 services
Medicare patients, 2024
1,214
Average age 75
Drug cost, 2024
$6.5M
1,869 prescriptions
Company payments, 2025
$4,474
From 42 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel M Ibach was code J9271 (injection, pembrolizumab, 1 mg), 28,600 times for 22 patients. In total Daniel M Ibach billed 398,990 services in 175 codes, and Medicare paid $8.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 28,600 | 22 | $44.61 | $1.3M |
| J0897 Injection, denosumab, 1 mg | Office | 27,060 | 117 | $20.48 | $554K |
| J9299 Injection, nivolumab, 1 mg | Office | 23,500 | 14 | $24.64 | $579K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 21,420 | 19 | $0.26 | $5,512 |
| J0185 Injection, aprepitant, 1 mg | Office | 19,240 | 31 | $1.35 | $26K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 18,600 | 15 | $2.30 | $43K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 18,000 | 12 | $0.05 | $990 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 18,000 | 127 | $15.83 | $285K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 17,460 | 17 | $35.64 | $622K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 14,388 | 31 | $21.19 | $305K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 8,480 | 13 | $35.44 | $301K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 5,532 | 86 | $0.09 | $496 |
| 85025 Blood Count | Office | 3,657 | 971 | $7.52 | $27K |
| Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Office | 3,626 | 14 | $50.72 | $184K |
| 80053 Clinical Chemistry | Office | 3,178 | 949 | $10.32 | $33K |
By year: 2022 $7.5M for 465,431 services; 2023 $7.5M for 410,554 services; 2024 $8.5M for 398,990 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 3,657 | 971 | $7.52 | $27K |
| 80053 Clinical Chemistry | 3,178 | 949 | $10.32 | $33K |
| 36415 Venipuncture Blood Collection | 3,111 | 931 | $8.52 | $27K |
| 83615 Clinical Chemistry | 2,018 | 753 | $5.90 | $12K |
| 82784 Immunoassay | 1,135 | 129 | $9.09 | $10K |
| 83540 Clinical Chemistry | 1,113 | 511 | $6.30 | $7,014 |
| 82728 Clinical Chemistry | 1,109 | 509 | $13.28 | $15K |
| 83550 Clinical Chemistry | 1,103 | 507 | $8.52 | $9,396 |
| 88185 Surgical Pathology Examination | 975 | 37 | $15.66 | $15K |
| 82607 Clinical Chemistry | 830 | 426 | $14.76 | $12K |
Medicare prescription drug claims, 2024
In 2024, the drug Daniel M Ibach prescribed most often to Medicare patients was Letrozole, with 246 prescriptions and refills. In total Daniel M Ibach wrote 1,869 Medicare prescriptions that cost $6.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 246 | 624 | 67 | $3,404 |
| Eliquis Apixaban | 91 | 128 | 25 | $73K |
| Ondansetron Hcl Generic | 89 | 89 | 48 | $1,045 |
| Revlimid Lenalidomide | 63 | 63 | 12 | $1.0M |
| Lenalidomide Generic | 61 | 61 | Under 11 | $685K |
| Folic Acid Generic | 52 | 100 | 11 | $225 |
| Dexamethasone Generic | 52 | 65 | 14 | $1,685 |
| Prednisone Generic | 52 | 63 | 21 | $165 |
| Imbruvica Ibrutinib | 50 | 51 | Under 11 | $702K |
| Prochlorperazine Maleate Generic | 43 | 45 | 14 | $498 |
| Kisqali Ribociclib Succinate | 43 | 43 | Under 11 | $595K |
| Levothyroxine Sodium Generic | 41 | 85 | 13 | $301 |
| Exemestane Generic | 41 | 97 | 12 | $4,889 |
| Hydroxyurea Generic | 40 | 75 | Under 11 | $1,025 |
| Tamoxifen Citrate Generic | 38 | 112 | 13 | $968 |
Brand drugs: 570 claims; generic drugs: 1,299 claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel M Ibach $4,474 ($4,474 in general payments such as food, travel and fees) from 42 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $378.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 15 | $378 |
| Janssen Biotech, Inc. JNJ | 12 | $362 |
| E.R. Squibb & Sons, L.L.C. BMY | 18 | $309 |
| Pfizer Inc. PFE | 12 | $261 |
| Merck Sharp & Dohme LLC MRK | 9 | $256 |
| Regeneron Healthcare Solutions, Inc. REGN | 9 | $253 |
| Novartis Pharmaceuticals Corporation NVS | 16 | $246 |
| Incyte Corporation INCY | 8 | $216 |
| Abbvie Inc. ABBV | 9 | $190 |
| Celgene Corporation BMY | 11 | $187 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.